Skip to content
Sign in — free
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Oct 25, 2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

A forensic read on Corbus Pharmaceuticals Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk
Forensic grade
Distress
Financial health
-1.0
Distress distance
Clean
Earnings quality
2
Forensic signals
-54.2%
ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Corbus Pharmaceuticals Holdings, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -1.0, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+75.4%/yr
FY2023–FY2025
Share-count dilution. Diluted share count changed +208% over the last 2 years to FY2025 (+75.4%/yr). The count is growing — 4.3M shares in FY2023, 13.3M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~75.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~68%.
-118.7% of rev
FY2023
Stock-based comp load. Stock-based compensation ran -118.7% of revenue in FY2023 — about $0.80 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 75.4% a year across FY2023–FY2025, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.

Key fundamentals

Latest Revenue-$2.9M
Net Margin1525.5%
Free Cash Flow-$64.5M
Return on Equity-54.2%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Corbus Pharmaceuticals Holdings, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Oct 25, 2026. Forensic signals flag probability, not certainty.